MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
18 01 2022
18 01 2022
Historique:
received:
29
03
2021
accepted:
19
10
2021
revised:
21
09
2021
entrez:
19
1
2022
pubmed:
20
1
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Colorectal cancer (CRC) is one of the most common and deadliest forms of cancer. Myeloid Cell Leukemia 1 (MCL1), a pro-survival member of the Bcl-2 protein family is associated with chemo-resistance in CRC. The ability of MCL1 to inhibit apoptosis by binding to the BH3 domains of pro-apoptotic Bcl-2 family members is a well-studied means by which this protein confers resistance to multiple anti-cancer therapies. We found that specific DNA damaging chemotherapies promote nuclear MCL1 translocation in CRC models. In p53
Identifiants
pubmed: 35042842
doi: 10.1038/s41419-021-04334-y
pii: 10.1038/s41419-021-04334-y
pmc: PMC8766550
doi:
Substances chimiques
MCL1 protein, human
0
Myeloid Cell Leukemia Sequence 1 Protein
0
Proto-Oncogene Proteins c-bcl-2
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
63Subventions
Organisme : NCI NIH HHS
ID : R01 CA244958
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Aubrey BJ, Janic A, Chen Y, Chang C, Lieschke EC, Diepstraten ST, et al. Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor development. Genes Dev. 2018;32:1420–9.
pmcid: 6217734
pubmed: 30366906
doi: 10.1101/gad.314286.118
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet 2019;394:1467–80.
pubmed: 31631858
doi: 10.1016/S0140-6736(19)32319-0
Mantovani F, Collavin L, Del, Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019;26:199–212.
pubmed: 30538286
doi: 10.1038/s41418-018-0246-9
Nakayama M, Oshima M. Mutant p53 in colon cancer. J Mol Cell Biol. 2019;11:267–76.
pubmed: 30496442
doi: 10.1093/jmcb/mjy075
Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 2016;538:477–82.
pubmed: 27760111
doi: 10.1038/nature19830
Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J, et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis. 2015;6:e1590.
pmcid: 4669759
pubmed: 25590800
doi: 10.1038/cddis.2014.561
Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–8.
pubmed: 23291630
doi: 10.1038/nm.3048
Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421–8.
pubmed: 18451170
doi: 10.1158/0008-5472.CAN-07-5836
Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl J Med. 2016;374:311–22.
pubmed: 26639348
doi: 10.1056/NEJMoa1513257
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N. Engl J Med. 2018;378:1107–20.
pubmed: 29562156
doi: 10.1056/NEJMoa1713976
Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Disco. 2016;6:1106–17.
doi: 10.1158/2159-8290.CD-16-0313
DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 2019;133:7–17.
pmcid: 6318429
pubmed: 30361262
doi: 10.1182/blood-2018-08-868752
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31–42.
pubmed: 30518502
doi: 10.1016/S1470-2045(18)30864-7
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010;463:899–905.
pmcid: 2826709
pubmed: 20164920
doi: 10.1038/nature08822
Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015;7:279ra40.
pubmed: 25787766
doi: 10.1126/scitranslmed.aaa4642
Weeden CE, Ah-Cann C, Holik AZ, Pasquet J, Garnier JM, Merino D, et al. Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition. Oncogene 2018;37:4475–88.
pubmed: 29743589
doi: 10.1038/s41388-018-0268-2
Zhang H, Xue J, Hessler P, Tahir SK, Chen J, Jin S, et al. Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer. Mol Cancer. 2015;14:126.
pmcid: 4487849
pubmed: 26134786
doi: 10.1186/s12943-015-0397-y
Kawakami H, Huang S, Pal K, Dutta SK, Mukhopadhyay D, Sinicrope FA. Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer. Mol Cancer Ther. 2016;15:3015–27.
pmcid: 5136313
pubmed: 27765849
doi: 10.1158/1535-7163.MCT-16-0017
Tong J, Wang P, Tan S, Chen D, Nikolovska-Coleska Z, Zou F, et al. Mcl-1 degradation is required for targeted therapeutics to eradicate colon cancer cells. Cancer Res. 2017;77:2512–21.
pmcid: 5626525
pubmed: 28202514
doi: 10.1158/0008-5472.CAN-16-3242
Wei G, Margolin AA, Haery L, Brown E, Cucolo L, Julian B, et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell. 2012;21:547–62.
pmcid: 3685408
pubmed: 22516262
doi: 10.1016/j.ccr.2012.02.028
Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 2018;25:27–36.
pubmed: 29099483
doi: 10.1038/cdd.2017.161
Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB, et al. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 2013;27:1365–77.
pmcid: 3701192
pubmed: 23788623
doi: 10.1101/gad.215871.113
Wang X, Bathina M, Lynch J, Koss B, Calabrese C, Frase S, et al. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 2013;27:1351–64.
pmcid: 3701191
pubmed: 23788622
doi: 10.1101/gad.215855.113
Liu Y, Wei G, Cheng WA, Dong Z, Sun H, Lee VY, et al. Targeting myeloid-derived suppressor cells for cancer immunotherapy. Cancer Immunol Immunother. 2018;67:1181–95.
pubmed: 29855694
doi: 10.1007/s00262-018-2175-3
Demelash A, Pfannenstiel LW, Tannenbaum CS, Li X, Kalady MF, DeVecchio J, et al. Structure-function analysis of the Mcl-1 protein identifies a novel senescence-regulating domain. J Biol Chem. 2015;290:21962–75.
pmcid: 4571950
pubmed: 26205817
doi: 10.1074/jbc.M115.663898
Jamil S, Stoica C, Hackett TL, Duronio V. MCL-1 localizes to sites of DNA damage and regulates DNA damage response. Cell Cycle. 2010;9:2843–55.
pmcid: 3040962
pubmed: 20647761
doi: 10.4161/cc.9.14.12354
Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol. 2012;14:575−583.
Leroy B, Girard L, Hollestelle A, Minna JD, Gazdar AF, Soussi T. Analysis of TP53 mutation status in human cancer cell lines: a reassessment. Hum Mutat. 2014;35:756–65.
pmcid: 4451114
pubmed: 24700732
doi: 10.1002/humu.22556
Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol. 2012;14:575–83.
pmcid: 3401947
pubmed: 22544066
doi: 10.1038/ncb2488
Demelash A, Pfannenstiel LW, Liu L, Gastman BR. Mcl-1 regulates reactive oxygen species via NOX4 during chemotherapy-induced senescence. Oncotarget 2017;8:28154–68.
pmcid: 5438639
pubmed: 28423654
doi: 10.18632/oncotarget.15962
Bolesta E, Pfannenstiel LW, Demelash A, Lesniewski ML, Tobin M, Schlanger SE, et al. Inhibition of Mcl-1 promotes senescence in cancer cells: implications for preventing tumor growth and chemotherapy resistance. Mol Cell Biol. 2012;32:1879–92.
pmcid: 3347419
pubmed: 22451485
doi: 10.1128/MCB.06214-11
Sweitzer TD, Hanover JA. Calmodulin activates nuclear protein import: a link between signal transduction and nuclear transport. Proc Natl Acad Sci USA. 1996;93:14574–9.
pmcid: 26175
pubmed: 8962094
doi: 10.1073/pnas.93.25.14574
Yap KL, Kim J, Truong K, Sherman M, Yuan T, Ikura M. Calmodulin target database. J Struct Funct Genomics. 2000;1:8–14.
pubmed: 12836676
doi: 10.1023/A:1011320027914
Rodriguez-Mora OG, LaHair MM, McCubrey JA, Franklin RA. Calcium/calmodulin-dependent kinase I and calcium/calmodulin-dependent kinase kinase participate in the control of cell cycle progression in MCF-7 human breast cancer cells. Cancer Res. 2005;65:5408–16.
pubmed: 15958590
doi: 10.1158/0008-5472.CAN-05-0271
Bruncko M, Wang L, Sheppard GS, Phillips DC, Tahir SK, Xue J, et al. Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity. J Med Chem. 2015;58:2180–94.
pubmed: 25679114
doi: 10.1021/jm501258m
Rasmussen ML, Kline LA, Park KP, Ortolano NA, Romero-Morales AI, Anthony CC, et al. A non-apoptotic function of MCL-1 in promoting pluripotency and modulating mitochondrial dynamics in stem cells. Stem Cell Rep. 2018;10:684–92.
doi: 10.1016/j.stemcr.2018.01.005
Pawlikowska P, Leray I, de Laval B, Guihard S, Kumar R, Rosselli F, et al. ATM-dependent expression of IEX-1 controls nuclear accumulation of Mcl-1 and the DNA damage response. Cell Death Differ. 2010;17:1739–50.
pubmed: 20467439
doi: 10.1038/cdd.2010.56
Germain M, Duronio V. The N terminus of the anti-apoptotic BCL-2 homologue MCL-1 regulates its localization and function. J Biol Chem. 2007;282:32233–42.
pubmed: 17823113
doi: 10.1074/jbc.M706408200
Jamil S, Sobouti R, Hojabrpour P, Raj M, Kast J, Duronio V. A proteolytic fragment of Mcl-1 exhibits nuclear localization and regulates cell growth by interaction with Cdk1. Biochem J. 2005;387:659–67.
pmcid: 1134995
pubmed: 15554878
doi: 10.1042/BJ20041596
Hanover JA, Love DC, Prinz WA. Calmodulin-driven nuclear entry: trigger for sex determination and terminal differentiation. J Biol Chem. 2009;284:12593–7.
pmcid: 2675987
pubmed: 19126540
doi: 10.1074/jbc.R800076200
Abdoul-Azize S, Buquet C, Li H, Picquenot JM, Vannier JP. Integration of Ca(2+) signaling regulates the breast tumor cell response to simvastatin and doxorubicin. Oncogene 2018;37:4979–93.
pubmed: 29795329
doi: 10.1038/s41388-018-0329-6
Cappello P, Principe M, Bulfamante S, Novelli F. Alpha-Enolase (ENO1), a potential target in novel immunotherapies. Front Biosci. 2017;22:944–59.
doi: 10.2741/4526
Diaz-Ramos A, Roig-Borrellas A, Garcia-Melero A, Lopez-Alemany R. alpha-Enolase, a multifunctional protein: its role on pathophysiological situations. J Biomed Biotechnol. 2012;2012:156795.
pmcid: 3479624
pubmed: 23118496
doi: 10.1155/2012/156795
Chang GC, Liu KJ, Hsieh CL, Hu TS, Charoenfuprasert S, Liu HK, et al. Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin Cancer Res. 2006;12:5746–54.
pubmed: 17020980
doi: 10.1158/1078-0432.CCR-06-0324
Mikuriya K, Kuramitsu Y, Ryozawa S, Fujimoto M, Mori S, Oka M, et al. Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol. 2007;30:849–55.
pubmed: 17332923
Tsai ST, Chien IH, Shen WH, Kuo YZ, Jin YT, Wong TY, et al. ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction. Eur J Cancer. 2010;46:1712–23.
pubmed: 20435467
doi: 10.1016/j.ejca.2010.03.018
Widden H, Kaczmarczyk A, Subedi A, Whitaker RH, Placzek WJ. MCL1 binds and negatively regulates the transcriptional function of tumor suppressor p73. Cell Death Dis. 2020;11:946.
pmcid: 7641127
pubmed: 33144577
doi: 10.1038/s41419-020-03068-7
Backus HH, van Riel JM, van Groeningen CJ, Vos W, Dukers DF, Bloemena E, et al. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann Oncol. 2001;12:779–85.
pubmed: 11484952
doi: 10.1023/A:1011112227044
Zhang YL, Pang LQ, Wu Y, Wang XY, Wang CQ, Fan Y. Significance of Bcl-xL in human colon carcinoma. World J Gastroenterol. 2008;14:3069–73.
pmcid: 2712177
pubmed: 18494061
doi: 10.3748/wjg.14.3069
Dunne PD, Coleman HG, Bankhead P, Alderdice M, Gray RT, McQuaid S, et al. Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer. Oncotarget 2018;9:13834–47.
pmcid: 5862619
pubmed: 29568398
doi: 10.18632/oncotarget.24481
Ramesh P, Lannagan TRM, Jackstadt R, Atencia Taboada L, Lansu N, Wirapati P, et al. BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer. Cell Death Differ. 2021. https://doi.org/10.1038/s41418-021-00816-w .
Lee WS, Park YL, Kim N, Oh HH, Son DJ, Kim MY, et al. Myeloid cell leukemia-1 is associated with tumor progression by inhibiting apoptosis and enhancing angiogenesis in colorectal cancer. Am J Cancer Res. 2015;5:101–13.
pubmed: 25628923
Lathwal A, Arora C, Raghava GPS. Prediction of risk scores for colorectal cancer patients from the concentration of proteins involved in mitochondrial apoptotic pathway. PLoS One. 2019;14:e0217527.
pmcid: 6733437
pubmed: 31498794
doi: 10.1371/journal.pone.0217527
Qian X, Xu W, Xu J, Shi Q, Li J, Weng Y, et al. Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer. Oncotarget 2017;8:47691–708.
pmcid: 5564598
pubmed: 28548950
doi: 10.18632/oncotarget.17868